Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL8 | P10145 | 7/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL360591 | 0.84 | CXCL8 (0.65) | CXCL8MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL12129515 | 0.78 | CXCL8 (1.00) | CXCL8MEN1KMT2AMAPTGAA | |
| SCHEMBL3137707 | 0.78 | CXCL8 (1.00) | CXCL8MEN1KMT2AMAPTGAA | |
| SCHEMBL3151521 | 0.78 | CXCL8 (1.00) | CXCL8MEN1KMT2AMAPTGAA | |
| SCHEMBL27800319 | 0.74 | CXCL8 (0.53) | CXCL8MEN1KMT2AMAPTALDH1A1 | |
| Acetic Acid SCHEMBL1446325 | 0.74 | MAPT (0.59) | MEN1KMT2AMAPTRAB9ANPSR1 | |
| SCHEMBL1446469 | 0.73 | TTR (0.71) | MEN1KMT2AMAPTRAB9ADHODH | |
| SCHEMBL4944935 | 0.73 | CXCL8 (0.58) | CXCL8KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL7126780 | 0.72 | CXCL8 (0.82) | CXCL8KMT2ASMN1; SMN2DHODHGAA | |
| SCHEMBL16539266 | 0.72 | CXCL8 (0.64) | CXCL8MEN1KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021085-A1 | METHOD OF REDUCING ABETA42 AND TREATING DISEASES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080021085-A1 | METHOD OF REDUCING ABETA42 AND TREATING DISEASES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021085-A1 | METHOD OF REDUCING ABETA42 AND TREATING DISEASES | BACE1, BACE2, APP | CXCL8 4167/4885MEN1 1816/4885KMT2A 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.